

(3) Develop, implement, and manage novel, innovative scientific and technical programs to democratize access to life-saving innovations and reduce disparities in health outcomes across the United States. (4) Propose agency-sponsored research programs to the ARPA-H Director, ensuring they align with strategic objectives.

#### *The Proactive Health Office*

The Proactive Health Office (PHO) is comprised of:

1. Director
2. Deputy Director
3. Such other staff as necessary to support the PHO.

PHO's functions and responsibilities are as follows: (1) Improve personal health and wellness to reduce the likelihood that people will become patients. (2) Establish preventative programs that create new capabilities to identify and characterize disease risk, reduce comorbidities, and promote treatments and behaviors to address challenges to Americans' health, whether those are viral, bacterial, physical, psychological, or caused by the natural aging process. (3) Develop, implement, and manage novel, innovative scientific and technical programs aimed at improving health outcomes. (4) Propose agency-sponsored research programs to the ARPA-H Director, ensuring they align with strategic objectives.

#### *The Project Accelerator Transition Innovation Office*

The Project Accelerator Transition Innovation Office (PATIO) is comprised of:

1. Director
2. Deputy Director
3. Such other staff as necessary to support the PATIO.

PATIO's missions and responsibilities are as follows: (1) Increase the probability that solutions thrive independently after they transition from ARPA-H. (2) Provide a wide variety of services to Program Managers (PMs) and ARPA-H performers throughout the entire program lifecycle. (3) Provide a tailored, full-suite of entrepreneurial and tech-to-market services to ARPA-H program managers and performers, including access to C-suite level talent to advise on various topics: clinical, business, user adoption, manufacturing, landscape analysis, and regulatory matters. (4) Manage ARPA-H's Small Business Innovation Research (SBIR). (5) Ensure capabilities are primarily designed for user experience. Provide Minimum Viable Product (MVP) and market-testing experimentation to

uncover insights into customer desirability, access, and trust. (6) Maintain ARPANET-H, including the Investor Catalyst and Customer Experience Hub and Spoke Network to create a Nationwide Health Innovation Network for ARPA-H to help performers bring their ideas to market. (7) Develop a unique portfolio to address challenging problems related to health for fostering revolutionary advances and paradigm shifts. (8) Propose agency-sponsored research programs to the ARPA-H Director, ensuring they align with strategic objectives.

#### *The Office of Operations*

The Office of Operations (OO) is comprised of:

1. Director
2. Deputy Director
3. Such other staff as necessary to support the OO.

OO's functions and responsibilities are as follows: (1) Advise the ARPA-H Director and staff on the planning, development, and implementation of agency Business Operation services. (2) Lead all aspects of internal business operations, including ongoing management of the agency's financial and budget activities, human capital, contracting and acquisitions, and other administrative and operational activities including but not limited to travel and training. (3) Oversee the creation of relevant business operations Standard Operating Procedures (SOPs), develops tracking and reporting processes and tools, provides high-level input to inform legal and financial risk, and develops systems that support administrative processes within the agency. (4) Oversee the Agency's security related procedures and programs including research security risk and supply chain risk management. (5) Manage ARPA-H's regional footprint and associated infrastructure across hub locations, including facilities and space management. (6) Oversee management of ARPA-H's official records management in collaboration with Office of Information Technology and Data Innovation.

#### *The Office of Information Technology and Data Innovation*

The Office of Information Technology and Data Innovation (ITDI) is comprised of:

1. The Chief Technology Officer
2. The Chief Information Officer
3. The Chief Information and Security Officer
4. The Chief Data Officer
5. Such other staff as necessary to support the ITDI Office.

ITDI's functions and responsibilities are as follows: (1) Advise the ARPA-H Director, staff, and programs on every aspect of Information Technology (IT) and Data modernization, governance, and allocation of relevant technology and communication resources to drive the agency's mission. (2) Support the research, development, launch, and maintenance of tools to support data governance, innovation, and analytics across the agency, including data needs for program development. (3) Lead development of agency-wide IT, AI/ML, Technology Infrastructure, Cloud Computing, Networking, End User Computing, Cybersecurity, Technology Compliance, Telecommunications, and Responsible use of Technology Policy. (4) Develop and implement enterprise solutions to enable lean and agile business operations and collaboration. (5) Leads agency efforts to ensure user and data privacy and security management across all platforms and services. (6) Liaise with HHS and across the U.S. government to ensure compliance and consistency with U.S. government policy impacting IT tools and services, as well as data storage and analysis. (7) Conduct life cycle investment planning and monitoring as needed to support the areas listed above.

**Xavier Becerra,**

*Secretary, Department of Health and Human Services.*

[FR Doc. 2024-31364 Filed 12-26-24; 11:15 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases;

Initial Review Group Diabetes, Endocrinology and Metabolic Diseases B Study Section Diabetes, Endocrinology and Metabolic Diseases B Study Section (DDK-B).

*Date:* March 5–7, 2025.

*Time:* 10:00 a.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Charlene J. Repique, Ph.D., Scientific Review Officer, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Boulevard, Rm 7347, Bethesda, MD 20892–5452, (301) 451–3638, [charlene.repique@nih.gov](mailto:charlene.repique@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 20, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024–31180 Filed 12–30–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP–10: NCI Clinical and Translational Cancer Research.

*Date:* March 4, 2025.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W240, Rockville, Maryland 20850.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review

Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Rockville, Maryland 20850, 240–276–5122, [hasan.siddiqui@nih.gov](mailto:hasan.siddiqui@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Integrating Biospecimen Science Approaches into Clinical Assay Development.

*Date:* March 26, 2025.

*Time:* 1:00 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W624, Rockville, Maryland 20850.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Tushar Deb, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Rockville, Maryland 20850, 240–276–6132, [tushar.deb@nih.gov](mailto:tushar.deb@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 20, 2024.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024–31171 Filed 12–30–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Digestive Diseases and Nutrition C Study Section DDK–C Mentored

Career Development Applications in Digestive Diseases and Nutrition.

*Date:* March 19–20, 2025.

*Time:* 5:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Peter J. Kozel, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 7009, Bethesda, MD 20892–5452, (301) 594–4721, [kozelp@mail.nih.gov](mailto:kozelp@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 20, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024–31183 Filed 12–30–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Beeson applications review.

*Date:* February 25, 2025.

*Time:* 9:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institute on Aging, 5601 Fishers Lane, Suite 8B, Rockville, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Gianina Ramona Dumitrescu, Ph.D., MPH, Scientific Review Officer, National Institute on Aging, National